Literature DB >> 11427602

Novel fluorescent broth microdilution method for fluconazole susceptibility testing of Candida albicans.

R S Liao1, R P Rennie, J A Talbot.   

Abstract

A comparative evaluation of the reference National Committee for Clinical Laboratory Standards (NCCLS) broth microdilution method with a novel fluorescent carboxyfluorescein diacetate (CFDA)-modified microdilution method for the susceptibility testing of fluconazole was conducted with 68 Candida strains, including 53 Candida albicans, 5 Candida tropicalis, 5 Candida glabrata, and 5 Candida parapsilosis strains. We found trailing endpoints and discordant fluconazole MICs of < 8 microg/ml at 24 h and of > or =64 microg/ml at 48 h for 12 of the C. albicans strains. These strains satisfy the definition of the low-high MIC phenotype. All 12 low-high phenotype strains were correctly shown to be susceptible at 48 h with the CFDA-modified microdilution method. For the 41 non-low-high phenotype C. albicans strains, the CFDA-modified microdilution method yielded 97.6% (40 of 41 strains) agreement within +/-1 dilution at 24 h compared with the reference method and 92.7% (38 of 41 strains) agreement within +/-1 dilution at 48 h compared with the reference method. The five strains each from C. tropicalis, C. glabrata, and C. parapsilosis that were tested showed 100% agreement within +/-2 dilutions for the two methods being evaluated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11427602      PMCID: PMC88218          DOI: 10.1128/JCM.39.7.2708-2712.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  25 in total

1.  Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis.

Authors:  J H Rex; P W Nelson; V L Paetznick; M Lozano-Chiu; A Espinel-Ingroff; E J Anaissie
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

Review 2.  International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections.

Authors:  J E Edwards; G P Bodey; R A Bowden; T Büchner; B E de Pauw; S G Filler; M A Ghannoum; M Glauser; R Herbrecht; C A Kauffman; S Kohno; P Martino; F Meunier; T Mori; M A Pfaller; J H Rex; T R Rogers; R H Rubin; J Solomkin; C Viscoli; T J Walsh; M White
Journal:  Clin Infect Dis       Date:  1997-07       Impact factor: 9.079

3.  Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998.

Authors:  M A Pfaller; R N Jones; G V Doern; H S Sader; S A Messer; A Houston; S Coffman; R J Hollis
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

4.  Hospital-acquired candidemia. The attributable mortality and excess length of stay.

Authors:  S B Wey; M Mori; M A Pfaller; R F Woolson; R P Wenzel
Journal:  Arch Intern Med       Date:  1988-12

5.  Comparison of visual and spectrophotometric methods of MIC endpoint determinations by using broth microdilution methods to test five antifungal agents, including the new triazole D0870.

Authors:  M A Pfaller; S A Messer; S Coffmann
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

6.  The trailing end point phenotype in antifungal susceptibility testing is pH dependent.

Authors:  K A Marr; T R Rustad; J H Rex; T C White
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

7.  Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method.

Authors:  S G Revankar; W R Kirkpatrick; R K McAtee; A W Fothergill; S W Redding; M G Rinaldi; T F Patterson
Journal:  J Clin Microbiol       Date:  1998-01       Impact factor: 5.948

8.  Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System.

Authors:  C Beck-Sagué; W R Jarvis
Journal:  J Infect Dis       Date:  1993-05       Impact factor: 5.226

Review 9.  Current and emerging azole antifungal agents.

Authors:  D J Sheehan; C A Hitchcock; C M Sibley
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

10.  Trends and sources of nosocomial fungaemia.

Authors:  G D Taylor; M Buchanan-Chell; T Kirkland; M McKenzie; R Wiens
Journal:  Mycoses       Date:  1994 Jun-Jul       Impact factor: 4.377

View more
  4 in total

1.  Use of fluorescent probes to determine MICs of amphotericin B and caspofungin against Candida spp. and Aspergillus spp.

Authors:  Joanne Peter; Derek Armstrong; Caron A Lyman; Thomas J Walsh
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

2.  The Mycotoxin Zearalenone Hinders Candida albicans Biofilm Formation and Hyphal Morphogenesis.

Authors:  Satish Kumar Rajasekharan; Jin-Hyung Lee; Yueju Zhao; Jintae Lee
Journal:  Indian J Microbiol       Date:  2017-11-04       Impact factor: 2.461

3.  Comparative evaluation of a new fluorescent carboxyfluorescein diacetate-modified microdilution method for antifungal susceptibility testing of Candida albicans isolates.

Authors:  Robert S Liao; Robert P Rennie; James A Talbot
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

4.  Conidial viability assay for rapid susceptibility testing of Aspergillus species.

Authors:  S Arunmozhi Balajee; Kieren A Marr
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.